BR112023025827A2 - Composto antagonista de canal trpa1 para uso em doenças degenerativas da retina - Google Patents

Composto antagonista de canal trpa1 para uso em doenças degenerativas da retina

Info

Publication number
BR112023025827A2
BR112023025827A2 BR112023025827A BR112023025827A BR112023025827A2 BR 112023025827 A2 BR112023025827 A2 BR 112023025827A2 BR 112023025827 A BR112023025827 A BR 112023025827A BR 112023025827 A BR112023025827 A BR 112023025827A BR 112023025827 A2 BR112023025827 A2 BR 112023025827A2
Authority
BR
Brazil
Prior art keywords
channel antagonist
trpa1 channel
antagonist compound
retinal diseases
degenerative retinal
Prior art date
Application number
BR112023025827A
Other languages
English (en)
Inventor
DE LOGU Francesco
Pierangelo Geppetti
Romina Nassini
Original Assignee
Flonext S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flonext S R L filed Critical Flonext S R L
Publication of BR112023025827A2 publication Critical patent/BR112023025827A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

omposto antagonista de canal trpa1 para uso em doenças degenerativas da retina. a presente invenção se refere a compostos antagonistas de canal trpa1 para uso na prevenção e/ou tratamento de doenças da retina, em particular na prevenção e/ou tratamento da degeneração macular. a presente invenção também se refere a uma composição oftálmica que compreende pelo menos um composto antagonista de canal trpa1 para uso oftálmico tópico na prevenção e/ou tratamento de pelo menos uma doença degenerativa da retina, de preferência degeneração macular
BR112023025827A 2021-06-09 2022-06-07 Composto antagonista de canal trpa1 para uso em doenças degenerativas da retina BR112023025827A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102021000015098A IT202100015098A1 (it) 2021-06-09 2021-06-09 Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
PCT/IB2022/055276 WO2022259133A1 (en) 2021-06-09 2022-06-07 Trpa1 channel antagonist compound for use in degenerative retinal diseases

Publications (1)

Publication Number Publication Date
BR112023025827A2 true BR112023025827A2 (pt) 2024-02-27

Family

ID=77801827

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025827A BR112023025827A2 (pt) 2021-06-09 2022-06-07 Composto antagonista de canal trpa1 para uso em doenças degenerativas da retina

Country Status (8)

Country Link
EP (1) EP4351540A1 (pt)
KR (1) KR20240019817A (pt)
CN (1) CN117460501A (pt)
BR (1) BR112023025827A2 (pt)
CA (1) CA3222168A1 (pt)
IL (1) IL308591A (pt)
IT (1) IT202100015098A1 (pt)
WO (1) WO2022259133A1 (pt)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508784A (ja) 2008-01-04 2011-03-17 アボット・ラボラトリーズ Ｔｒｐａ１アンタゴニスト
EP2249820A1 (en) 2008-01-04 2010-11-17 Abbott Laboratories Trpa1 antagonists
JP5559156B2 (ja) 2008-06-02 2014-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ３，４−ジヒドロピリミジンｔｒｐａ１アンタゴニスト
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
JP2013507364A (ja) 2009-10-07 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 新規なｔｒｐａ１アンタゴニスト
WO2012050641A2 (en) 2010-06-08 2012-04-19 Hydra Biosciences, Inc Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
JP5847827B2 (ja) 2010-10-12 2016-01-27 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｔｒｐａ１受容体アンタゴニスト
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
CA2843965A1 (en) 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1
JP6182072B2 (ja) 2012-01-17 2017-08-16 Ｅａファーマ株式会社 複素環アミド誘導体及びそれを含有する医薬
CN104684899B (zh) 2012-09-27 2017-07-04 霍夫曼-拉罗奇有限公司 取代的磺酰胺化合物
CN104822653B (zh) 2012-10-01 2017-03-08 奥赖恩公司 N‑丙‑2‑炔基甲酰胺衍生物及其作为trpa1拮抗剂的用途
EP2906544A1 (en) 2012-10-12 2015-08-19 F. Hoffmann-La Roche AG Substituted phenylcarbamate compounds
EP2909170A1 (en) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists
WO2014072325A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag [3-heteroaryl-2-trifluoromethyl-propyl]-piperidin-1-yle or -morpholin-4-yle compounds as trpa1 antagonists for the treatment of respiratory diseases
EP3055302B1 (en) 2013-10-11 2018-12-26 F. Hoffmann-La Roche AG Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators
MX2016004741A (es) 2013-10-15 2016-07-26 Glenmark Pharmaceuticals Sa Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
JP6626454B2 (ja) 2014-01-06 2019-12-25 アルゴメディクス インコーポレイテッド Ｔｒｐａ１モジュレーター
BR112016017317B1 (pt) 2014-01-28 2023-04-11 EA Pharma Co., Ltd Composto, e, uso de um composto
TW201620877A (zh) 2014-03-28 2016-06-16 奧利安公司 新的醫藥化合物
TW201620876A (zh) 2014-03-28 2016-06-16 奧利安公司 新的醫藥化合物
WO2015155306A1 (en) 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
TWI676626B (zh) 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US10221177B2 (en) 2014-09-19 2019-03-05 Hydra Biosciences, Inc. Inhibiting the transient receptor potential A1 ion channel
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
CR20170367A (es) 2015-02-15 2017-09-12 Hoffmann La Roche Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
JPWO2017018495A1 (ja) 2015-07-29 2018-05-17 Ｅａファーマ株式会社 シクロプロパン誘導体及びそれを含有する医薬
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
WO2017135462A1 (ja) 2016-02-05 2017-08-10 Ｅａファーマ株式会社 複素環スルホンアミド誘導体及びそれを含有する医薬
SG11201811655SA (en) 2016-07-06 2019-01-30 Algomedix Inc Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation
WO2018015410A1 (en) 2016-07-20 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic proline compounds
WO2018015411A1 (en) 2016-07-20 2018-01-25 F. Hoffmann-La Roche Ag Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
JP7071959B2 (ja) 2016-08-12 2022-05-19 エフ．ホフマン－ラ ロシュ アーゲー スルホニルピリジルｔｒｐ阻害剤
TW201831477A (zh) 2016-11-28 2018-09-01 瑞士商赫孚孟拉羅股份公司 噁二唑酮瞬時受體電位通道抑制劑
EP3592739A1 (en) 2017-03-07 2020-01-15 H. Hoffnabb-La Roche Ag Oxadiazole transient receptor potential channel inhibitors
JP7025555B2 (ja) 2018-01-31 2022-02-24 イーライ リリー アンド カンパニー 一過性受容体電位ａ１イオンチャネルの阻害
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN110357833B (zh) 2019-06-03 2022-05-24 杭州维坦医药科技有限公司 芳杂乙酰胺类衍生物及其制备和应用
CN114555601B (zh) 2019-10-15 2024-04-02 勃林格殷格翰国际有限公司 新颖的四唑类

Also Published As

Publication number Publication date
IT202100015098A1 (it) 2022-12-09
EP4351540A1 (en) 2024-04-17
CN117460501A (zh) 2024-01-26
CA3222168A1 (en) 2022-12-15
WO2022259133A1 (en) 2022-12-15
IL308591A (en) 2024-01-01
KR20240019817A (ko) 2024-02-14

Similar Documents

Publication Publication Date Title
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
WO2007046083A3 (en) Compositions for treatment of eye diseases
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR112022003514A2 (pt) Degradadores bifuncionais de brd9 e seus métodos de uso
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
AU2018218696B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
BR112012015188A8 (pt) composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
BR112021011325A2 (pt) Derivados de rapamicina
EP3934646A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR DISEASES OR DISORDERS
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
BR112018014525A2 (pt) compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
MX2020009132A (es) Composiciones farmaceuticas que comprenden nebivolol.
BR112023025827A2 (pt) Composto antagonista de canal trpa1 para uso em doenças degenerativas da retina
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders
BR112021018222A2 (pt) Composição
BR112023002089A2 (pt) Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
BR112023019496A2 (pt) Derivados de ciclobutila 1,3-substituída e usos dos mesmos
AU2020299145A8 (en) Compositions and methods for treating eye diseases
BR112022015869A2 (pt) Composto, composição farmacêutica, métodos para inibir a ceto-hexoquinase e de tratamento e/ou prevenção de uma doença ou distúrbio, e, uso de um composto